SCHEMBL10046505

SCHEMBL10046505

NCC(=O)NCC(=O)N(CC(=O)O)CC(=O)NCC(=O)NCC(=O)N(CC(=O)O)CC(=O)NCCNC(=O)CN(CC(=O)O)C(=O)CNC(=O)CNC(=O)CN(CC(=O)O)C(=O)CNC(=O)CN

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
TERT O14746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19204219 0.97 CA1 (0.31) CA1CA2
SCHEMBL19523382 0.93
SCHEMBL19204179 0.93
SCHEMBL16264079 0.93 MEN1 (0.35)
SCHEMBL15500315 0.92
SCHEMBL10046525 0.88 EPHX2 (0.38)
SCHEMBL19523385 0.88
SCHEMBL12976858 0.85
SCHEMBL17690255 0.84 MCL1 (0.30)
SCHEMBL10046297 0.84 EPHX2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919941-B2 Functional lipid constructs KODE BIOTECH LIMITED (NZ) 2021-02-16 US disclosed
US-9802981-B2 Functional lipid constructs KODE BIOTECH LIMITED (NZ) 2017-10-31 US disclosed
US-20170218027-A1 FUNCTIONAL LIPID CONSTRUCTS KODE BIOTECH LIMITED (NZ) 2017-08-03 US disclosed
US-20140350217-A1 FUNCTIONAL LIPID CONSTRUCTS KODE BIOTECH LIMITED (NZ) 2014-11-27 US disclosed
US-8669084-B2 Functional lipid constructs KODE BIOTECH LIMITED (NZ) 2014-03-11 US disclosed
US-20120021430-A1 FUNCTIONAL LIPID CONSTRUCTS KODE BIOTECH LIMITED (NZ) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170218027-A1 FUNCTIONAL LIPID CONSTRUCTS CETP, LCAT, LIPA CA1 1029/4885CA2 2207/4885TERT 2332/4885
US-10919941-B2 Functional lipid constructs CETP, LCAT, LIPA CA1 1029/4885CA2 2207/4885TERT 2332/4885
US-20140350217-A1 FUNCTIONAL LIPID CONSTRUCTS CETP, LCAT, SGMS1 CA1 557/4885CA2 1281/4885TERT 2472/4885
US-20120021430-A1 FUNCTIONAL LIPID CONSTRUCTS CETP, LCAT, SGMS1 CA1 557/4885CA2 1281/4885TERT 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.